$3.07▴ 0.33%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Editas Medicine, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast